| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| bevacizumab erlotinib renal cell carcinoma | 0.92 | 0.7 | 6447 | 74 | 42 |
| bevacizumab | 1.57 | 0.9 | 465 | 8 | 11 |
| erlotinib | 0.16 | 0.7 | 8452 | 39 | 9 |
| renal | 0.61 | 0.5 | 2905 | 78 | 5 |
| cell | 1.18 | 0.2 | 3597 | 79 | 4 |
| carcinoma | 0.26 | 0.6 | 894 | 17 | 9 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| bevacizumab erlotinib renal cell carcinoma | 0.53 | 0.2 | 6283 | 45 |
| nivolumab cabozantinib renal cell carcinoma | 0.26 | 0.9 | 1680 | 5 |
| lenvatinib/pembrolizumab renal cell carcinoma | 0.55 | 1 | 5517 | 84 |
| renal cell carcinoma nivolumab | 0.93 | 0.2 | 934 | 26 |
| nivolumab for renal cell carcinoma nejm | 1.97 | 0.7 | 8147 | 27 |
| renal cell carcinoma pembrolizumab | 1.38 | 0.1 | 5047 | 38 |
| pembrolizumab adjuvant renal cell carcinoma | 0.32 | 0.4 | 8955 | 66 |
| nivolumab for renal cell carcinoma treatment | 1.66 | 1 | 5633 | 48 |
| bevacizumab in lung cancer | 0.7 | 0.7 | 8876 | 51 |
| nivolumab and cabozantinib in rcc | 0.59 | 0.2 | 4850 | 87 |
| everolimus and bevacizumab rcc | 0.85 | 0.4 | 4796 | 84 |
| bevacizumab in colorectal cancer | 0.69 | 1 | 6272 | 95 |
| bevacizumab metastatic colorectal cancer | 1.85 | 0.5 | 6097 | 4 |
| bevacizumab-bvzr | 1.14 | 1 | 9293 | 95 |
